Related Experiment Video
Updated: Jan 22, 2026

Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
Integrative Unani pharmacotherapy in chronic gastroesophageal reflux disease: A case report
1Assistant Professor, Department of Moalajat, National Institute of Unani Medicine, Ghaziabad, India.
Background:
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder that often requires prolonged proton pump inhibitor (PPI) therapy. It frequently coexists with Helicobacter pylori-associated gastritis. Limitations of long-term PPI use, symptom recurrence, and patient adherence have increased interest in complementary medical systems. Unani system of medicine (USM) conceptualizes reflux-like disorders as disturbances of digestion and gastric temperament, emphasizing mucosal protection and physiological restoration.
Case Presentation:
A 39-year-old man with a four-year history of severe GERD presented with persistent heartburn, regurgitation, epigastric burning, nausea, and sleep disturbance. Baseline investigations revealed H. pylori associated pangastritis in endoscopy, and Grade II-III reflux on barium swallow. After a brief course of conventional triple therapy for background gastritis, a structured 12-week Unani regimen was initiated as the primary intervention for GERD. Lifestyle corrections and dietary counseling were also provided. PPI therapy was discontinued after two weeks. Clinical symptoms, quality of life scores, imaging findings, and safety parameters were monitored.
Results:
The patient demonstrated progressive and clinically meaningful improvement with marked reduction in GERD-HRQL scores. Follow-up endoscopy showed descriptive improvement in gastric mucosa, and barium swallow findings normalized by week 14. The laboratory test results remained normal, and no adverse effects were reported. Clinical improvement was maintained at six-month follow-up without PPI use.
Conclusion:
In this case, a structured Unani regimen administered after short-term conventional therapy was temporally associated with improvement in chronic GERD symptoms and functional outcomes. Although gastritis improved descriptively, post-treatment H. pylori eradication was not assessed. Given the inherent limitations of a single-patient design, controlled clinical studies are required to confirm the efficacy and elucidate the mechanisms.
Related Concept Videos
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Kidney Disease I: Introduction
Psychosis: Goals of Pharmacotherapy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

